COVID-19 Vaccine Manufacturing
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent Biosolutions
PR-M07-20-NI-007Jul 07, 2020
Capacity Expansion
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Emergent Biosolutions
PR-M06-20-NI-029Jun 23, 2020
Biotechnology
CMO Services Built on a Culture of Agility
Emergent Biosolutions
PTV-M08-19-BIO-006Aug 12, 2019
Fill/Finish
Fill/Finish: Increasing Investment and Flexibility for Effective Manufacturing
B.J. Hull
Emergent Biosolutions
PAP-Q1-2019-CL-029Mar 12, 2019
Announcement
Baltimore Biotech Earns International Recognition for Advanced Development and Manufacturing Facility
Emergent Biosolutions
PR-M01-19-NI-020Jan 04, 2019
Acquisition
Emergent BioSolutions to Acquire PaxVax from Cerberus Capital Management
PaxVax
PR-M08-18-NI-114Aug 30, 2018
Acquisition
Emergent BioSolutions Expands Its Drug Portfolio Through Two Acquisitions
Emilie Branch
Pharma's Almanac
PAO-M07-17-NI-030Jul 25, 2017